Application of composition in preparation of medicine for treating amyotrophic lateral sclerosis

A technology for lateral sclerosis and muscular atrophy, which is applied in the directions of drug combination, active ingredients of hydroxyl compounds, and pharmaceutical formulations, and can solve problems such as inability to judge and predict therapeutic effects.

Pending Publication Date: 2021-10-29
JIANGSU SIMCERE PHARMA +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Based on the prior art, it is not possible to predict whether a combination of 3-methyl-1-phenyl-2-pyrazolin-5-one and borneol will have a therapeutic effect on amyotrophic lateral sclerosis and related disorders, nor can it Judging whether the composition of 3-methyl-1-phenyl-2-pyrazolin-5-one and borneol with a mass ratio of 4:1 can produce synergistic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of composition in preparation of medicine for treating amyotrophic lateral sclerosis
  • Application of composition in preparation of medicine for treating amyotrophic lateral sclerosis
  • Application of composition in preparation of medicine for treating amyotrophic lateral sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Research on the therapeutic effect of the composition of edaravone and borneol on transgenic amyotrophic lateral sclerosis mice

[0033] 1 Materials and methods

[0034] 1.1 Test animals

[0035] Transgenic mice (B6SJL-TgN[SOD1-G93A]1Gur) carrying human copper / zinc superoxide dismutase (SOD1) (G93A mutant) and wild-type B6SJL F1 mice were purchased from Nanjing University. Breeding and breeding methods of mice: A wild-type female mouse is mated with a transgenic male mouse, and the offspring are identified by polymerase chain reaction (PCR) using the DNA extracted from the tail of the young mouse.

[0036] 1.2 Drugs and reagents

[0037] Edaravone and Borneolum composition, mass ratio 4:1 (described Borneolum is 2-borneol);

[0038] Edaravone (chemical name: 3-methyl-1-phenyl-2-pyrazolin-5-one);

[0039] Borneol (chemical name: 2-borneol).

[0040] 1.3 Test method

[0041] 1.3.1 Breeding and screening of B6SJL-TgN(SOD1-G93A)1Gur mice:

[0042] Five B6S...

Embodiment 2

[0064] Example 2: Effect of Edaravone and Borneol Composition on Learning and Memory of Transgenic Amyotrophic Lateral Sclerosis Mice

[0065] 1 Materials and methods

[0066] 1.1 Test animals

[0067] Transgenic mice (B6SJL-TgN[SOD1-G93A]1Gur) carrying human copper / zinc superoxide dismutase (SOD1) (G93A mutant) and wild-type B6SJL F1 mice were purchased from Nanjing University. Breeding and breeding methods of mice: A wild-type female mouse is mated with a transgenic male mouse, and the offspring are identified by polymerase chain reaction (PCR) using the DNA extracted from the tail of the young mouse.

[0068] 1.2 Drugs and reagents

[0069] Edaravone and borneol composition (the borneol is 2-borneol);

[0070] Edaravone (chemical name: 3-methyl-1-phenyl-2-pyrazolin-5-one);

[0071] Borneol (chemical name: 2-borneol).

[0072] 1.3 Test method

[0073] 1.3.1 Breeding and screening of B6SJL-TgN(SOD1-G93A)1Gur mice:

[0074] Five B6SJL-TgN(SOD1-G93A)1Gur male mice were m...

Embodiment 3

[0091] Example 3 Study on Therapeutic Effect of Edaravone and Borneolum Composition on Amyotrophic Lateral Sclerosis Transgenic Mice

[0092] 1 Materials and methods

[0093] 1.1 Test animals

[0094] Amyotrophic lateral sclerosis transgenic mice (B6SJL-Tg(SOD1*G93A)1Gur / JNju, hereinafter referred to as SOD1-G93A mice) and wild-type control mice were purchased from Nanjing University-Nanjing Institute of Biomedicine.

[0095] 1.2 Drugs and reagents

[0096] Edaravone and natural borneol composition (the mass ratio of edaravone and natural borneol is 4:1)

[0097] Edaravone

[0098] Riluzole

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of a composition in preparation of a medicine for treating amyotrophic lateral sclerosis and related disorders. The composition contains 3-methyl-1-phenyl-2-pyrazoline-5-one or pharmaceutically acceptable salt and borneol thereof. The medicine is a medicine for treating the amyotrophic lateral sclerosis in the onset time and the survival time, and is a medicine for improving the memory function defect of the amyotrophic lateral sclerosis.

Description

[0001] This application is a divisional application with an application date of June 8, 2016, an application number of 201680029994.7, and the title of the invention is "Application of a Composition in the Preparation of Drugs for the Treatment of Amyotrophic Lateral Sclerosis". [0002] This application claims the priority of the Chinese patent application submitted to the China Patent Office on June 10, 2015, with the application number 201510314584.4 and the title of the invention "A Composition in the Preparation of Drugs for the Treatment of Amyotrophic Lateral Sclerosis" , the entire contents of which are incorporated in this application by reference. technical field [0003] The invention belongs to the field of pharmacy, in particular to the combination of 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharmaceutically acceptable salt thereof and borneol in the treatment of amyotrophic lateral sclerosis and Application of relevant barriers. Background technique [0004] M...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4152A61P25/28A61P21/00A61K31/045
CPCA61K31/4152A61P25/28A61P21/00A61K31/045A61K2300/00
Inventor 杨士豹华垚张正平陈荣龚兆龙
Owner JIANGSU SIMCERE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap